Status:
TERMINATED
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia
Lead Sponsor:
Boston Medical Center
Conditions:
Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side...
Detailed Description
OBJECTIVES: Primary * Determine the maximum tolerated dose of autologous dendritic and leukemic fusion cell vaccine in patients with acute myeloid leukemia. * Determine the toxicity of this vaccine ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of acute myeloid leukemia (AML) by bone marrow biopsy
- Newly diagnosed
- Must have adequate dendritic cells and AML blasts isolated from bone marrow and/or peripheral blood
- No clinical evidence of CNS leukemia
- PATIENT CHARACTERISTICS:
- Age
- 18 and over
- Performance status
- Not specified
- Life expectancy
- Not specified
- Hematopoietic
- Not specified
- Hepatic
- Not specified
- Renal
- Not specified
- Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No clinically significant autoimmune disease
- No other active malignancy except nonmelanoma skin cancer
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- More than 3 months since prior immunotherapy
- Chemotherapy
- Not specified
- Endocrine therapy
- Not specified
- Radiotherapy
- Not specified
- Surgery
- Not specified
Exclusion
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00100971
Start Date
April 1 2004
End Date
March 1 2007
Last Update
January 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, United States, 02118